These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 34062733)
1. Concurrent Physiological and Pathological Angiogenesis in Retinopathy of Prematurity and Emerging Therapies. Dai C; Webster KA; Bhatt A; Tian H; Su G; Li W Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34062733 [TBL] [Abstract][Full Text] [Related]
2. Secretogranin III stringently regulates pathological but not physiological angiogenesis in oxygen-induced retinopathy. Dai C; Waduge P; Ji L; Huang C; He Y; Tian H; Zuniga-Sanchez E; Bhatt A; Pang IH; Su G; Webster KA; Li W Cell Mol Life Sci; 2022 Jan; 79(1):63. PubMed ID: 35006382 [TBL] [Abstract][Full Text] [Related]
3. Anti-secretogranin III therapy of oxygen-induced retinopathy with optimal safety. Tang F; LeBlanc ME; Wang W; Liang D; Chen P; Chou TH; Tian H; Li W Angiogenesis; 2019 Aug; 22(3):369-382. PubMed ID: 30644010 [TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Systemic Anti-Scg3 Therapy to Treat Oxygen-Induced Retinopathy. Dai C; Tian H; Bhatt A; Su G; Webster KA; Li W Front Biosci (Landmark Ed); 2022 Apr; 27(4):130. PubMed ID: 35468689 [TBL] [Abstract][Full Text] [Related]
5. Neurovascular abnormalities in retinopathy of prematurity and emerging therapies. Dai C; Xiao J; Wang C; Li W; Su G J Mol Med (Berl); 2022 Jun; 100(6):817-828. PubMed ID: 35394143 [TBL] [Abstract][Full Text] [Related]
7. Expression of vascular endothelial growth factor and pigment epithelial-derived factor in a rat model of retinopathy of prematurity. Hartmann JS; Thompson H; Wang H; Kanekar S; Huang W; Budd SJ; Hartnett ME Mol Vis; 2011; 17():1577-87. PubMed ID: 21738387 [TBL] [Abstract][Full Text] [Related]
8. Optimal Efficacy and Safety of Humanized Anti-Scg3 Antibody to Alleviate Oxygen-Induced Retinopathy. He Y; Tian H; Dai C; Wen R; Li X; Webster KA; Li W Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008775 [TBL] [Abstract][Full Text] [Related]
9. Astragalus root extract inhibits retinal cell apoptosis and repairs damaged retinal neovascularization in retinopathy of prematurity. Liu X; Wang B; Sun Y; Jia Y; Xu Z Cell Cycle; 2019 Nov; 18(22):3147-3159. PubMed ID: 31564208 [TBL] [Abstract][Full Text] [Related]
10. Secretogranin III: a diabetic retinopathy-selective angiogenic factor. Li W; Webster KA; LeBlanc ME; Tian H Cell Mol Life Sci; 2018 Feb; 75(4):635-647. PubMed ID: 28856381 [TBL] [Abstract][Full Text] [Related]
11. Celastrol inhibits pathologic neovascularization in oxygen-induced retinopathy by targeting the miR-17-5p/HIF-1α/VEGF pathway. Zhao K; Jiang Y; Zhang J; Shi J; Zheng P; Yang C; Chen Y Cell Cycle; 2022 Oct; 21(19):2091-2108. PubMed ID: 35695424 [TBL] [Abstract][Full Text] [Related]
12. The matricellular protein cysteine-rich protein 61 (CCN1/Cyr61) enhances physiological adaptation of retinal vessels and reduces pathological neovascularization associated with ischemic retinopathy. Hasan A; Pokeza N; Shaw L; Lee HS; Lazzaro D; Chintala H; Rosenbaum D; Grant MB; Chaqour B J Biol Chem; 2011 Mar; 286(11):9542-54. PubMed ID: 21212276 [TBL] [Abstract][Full Text] [Related]
13. Selectively targeting disease-restricted secretogranin III to alleviate choroidal neovascularization. Ji L; Waduge P; Hao L; Kaur A; Wan W; Wu Y; Tian H; Zhang J; Webster KA; Li W FASEB J; 2022 Jan; 36(1):e22106. PubMed ID: 34918375 [TBL] [Abstract][Full Text] [Related]
14. Protective effects of rapamycin on the retinal vascular bed during the vaso-obliteration phase in mouse oxygen-induced retinopathy model. Zhang J; Zhu M; Ruan L; Jiang C; Yang Q; Chang Q; Huang X FASEB J; 2020 Dec; 34(12):15822-15836. PubMed ID: 33103304 [TBL] [Abstract][Full Text] [Related]
15. Resveratrol, an Inhibitor Binding to VEGF, Restores the Pathology of Abnormal Angiogenesis in Retinopathy of Prematurity (ROP) in Mice: Application by Intravitreal and Topical Instillation. Hu WH; Zhang XY; Leung KW; Duan R; Dong TT; Qin QW; Tsim KW Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742898 [TBL] [Abstract][Full Text] [Related]
16. Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy. LeBlanc ME; Wang W; Chen X; Caberoy NB; Guo F; Shen C; Ji Y; Tian H; Wang H; Chen R; Li W J Exp Med; 2017 Apr; 214(4):1029-1047. PubMed ID: 28330905 [TBL] [Abstract][Full Text] [Related]
17. Molecular hydrogen promotes retinal vascular regeneration and attenuates neovascularization and neuroglial dysfunction in oxygen-induced retinopathy mice. Guo Y; Qin J; Sun R; Hao P; Jiang Z; Wang Y; Gao Z; Zhang H; Xie K; Zhang W Biol Res; 2024 Jun; 57(1):43. PubMed ID: 38915069 [TBL] [Abstract][Full Text] [Related]
18. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750 [TBL] [Abstract][Full Text] [Related]
19. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Sankar MJ; Sankar J; Chandra P Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009734. PubMed ID: 29308602 [TBL] [Abstract][Full Text] [Related]
20. Adenosine receptors and caffeine in retinopathy of prematurity. Chen JF; Zhang S; Zhou R; Lin Z; Cai X; Lin J; Huo Y; Liu X Mol Aspects Med; 2017 Jun; 55():118-125. PubMed ID: 28088487 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]